Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosentan for acute non-arteritic anterior ischemic optic neuropathy
2024-518345-21-00Phase 3Authorised
- Sponsor
- CHU Grenoble Alpes
- Start
- Jul 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of bosentan in non-arteritic anterior ischemic optic neuropathy (NAION), sponsored by CHU Grenoble Alpes. Primary endpoint: Average deficit in automated visual field 30-2. Planned start Jul 2015; status: authorised.
02
Drugs
bosentan
03
Conditions
non-arteritic anterior ischemic optic neuropathy (NAION)
Beyond the preview
Go deeper on 2024-518345-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518345-21-00.